Neuland Laboratories Ltd's Q4FY25 Quarter Results
- 16 May 2025
Result Summary
- Neuland Laboratories Ltd reported a 2.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 6.0%.
- Its expenses for the quarter were down by 9.6% QoQ and 2.2% YoY.
- The net profit decreased 33.5% QoQ and decreased 20.1% YoY.
- The earnings per share (EPS) of Neuland Laboratories Ltd stood at 52.7 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 390.37 | 401.94 | 415.14 | -2.9% | -6.0% |
Total Expenses | 298.16 | 329.95 | 304.97 | -9.6% | -2.2% |
Profit Before Tax | 92.20 | 127.76 | 110.16 | -27.8% | -16.3% |
Tax | 24.64 | 26.18 | 25.62 | -5.9% | -3.8% |
Profit After Tax | 67.56 | 101.59 | 84.54 | -33.5% | -20.1% |
Earnings Per Share | 52.70 | 79.20 | 65.90 | -33.5% | -20.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Neuland Laboratories Ltd is a well-established pharmaceutical company specializing in the manufacture and sale of active pharmaceutical ingredients (APIs). The company is known for its strong presence in the pharmaceutical industry, focusing on providing high-quality products to its global clientele. Neuland Laboratories has been operational for several decades and has built a reputation for reliability and scientific expertise. While specific recent developments are not provided in this context, the company is generally involved in ongoing research and development to enhance its product offerings and expand its market reach.
Revenue
For the quarter ending March 2025 (Q4FY25), Neuland Laboratories Ltd reported a total income of ₹390.37 crores. This represents a decrease of 2.9% compared to the previous quarter (Q3FY25), where the total income was ₹401.94 crores. Year-over-year, the total income showed a decline of 6.0% from ₹415.14 crores in Q4FY24. The decrease in total income both sequentially and annually may be indicative of market conditions or other operational factors impacting revenue generation during this period.
Profitability
The company's profitability for Q4FY25 reflected a profit before tax of ₹92.20 crores, which is a decline of 27.8% from the previous quarter's figure of ₹127.76 crores. Compared to the same quarter in the previous year (Q4FY24), the profit before tax decreased by 16.3% from ₹110.16 crores. The profit after tax for the current quarter was ₹67.56 crores, down by 33.5% from ₹101.59 crores in Q3FY25 and 20.1% lower than ₹84.54 crores in Q4FY24. The earnings per share for Q4FY25 were ₹52.70, reflecting the same percentage decrease as the profit after tax both QoQ and YoY.
Operating Metrics
Neuland Laboratories Ltd reported total expenses of ₹298.16 crores for Q4FY25, which is a reduction of 9.6% from the previous quarter's expenses of ₹329.95 crores. Year-over-year, the expenses showed a slight decrease of 2.2% from ₹304.97 crores in Q4FY24. The tax expense for the current quarter was ₹24.64 crores, reflecting a decrease of 5.9% from the previous quarter and a 3.8% decrease from the same quarter in the previous year. The decline in expenses both sequentially and annually contributed to the overall operating performance of the company during Q4FY25.